Uniseed began as a $20 million venture fund, founded by the Universities of Queensland and Melbourne. In 2005 through an investment commitment from Westscheme, Western Australia's largest non-government superannuation fund, the University of New South Wales and further investment from the founding Universities, the fund grew to over $60 million.

From 30 June 2011, AustralianSuper, one of Australia’s largest and best performing industry superannuation funds, took over responsibility for Westscheme’s portfolio and remaining investment commitment after a successor fund transfer.

Uniseed has a commitment to successfully commercialise the outcomes of Australian research and ingenuity from the University of Queensland, the University of Melbourne and the University of New South Wales.

It represents an important step in forging a link between academia and business that focuses on the commercialisation of innovative ideas and inventions for global consumption.

Uniseed has strong capabilities to package research outcomes from the academic research environment.

 

Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Postherpetic Neuralgia
(12/09/2011)

Hatchtech completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment DeOvo
(31/08/2011)

QRxPharma Completes NDS Submission for MoxDuo IR
(25/08/2011)

Spinifex Closes AU$18.25M Expanded Series B Round
(23/08/2011)

QRxPharma Announces A$35 Million Capital Raising to progress MoxDuo Formulations and Support Commercialisation of MoxDuo IRs
(22/07/2011)

QRxPharma Announces NDA Filing for MoxDuo IR
(18/07/2011)

$1.1m Sounds Good for Childhood Hearing Problems
(12/07/2011)

QRxPharma Completes Comparative Safety Study
(14/06/2011)

Verva Announces AUD 2M Financing and Results of Annual General Meeting
(13/05/2011)

TenasiTech pioneers nanotechnology for polyurethane industrial seals
(06/05/2011)

QRxPharama MoxDu IR Study
(06/05/2011)

Hatchtech commences 2b Clinical Trial of New-Generation Head Lice Treatment DeOvo
(06/05/2011)

Verva Announces Isis Pharmaceuticals, Inc. Adds FGFR Drug to Development Pipeline
(01/02/2011)

Changes to the Board at Uniseed
(31/12/2010)

QRxPharma Completes A$19.8 Million Capital Raising
(19/11/2010)

Hatchtech raises $6.3 For DeOvo head lice phase2b clinical trial
(26/10/2010)

QRxPharma Limited Announces A$14 Million Placement together with a Share Purchase Plan
(01/10/2010)

BT Imaging Closes Funding Round
(Marketwire - 23/08/10)

Frost & Sullivan recognises QRxPharma’s MoxDuo® IR for innovation in pain therapy
(18/08/2010)

QRxPharma receives positive feedback from scientific advice meetings in Europe on MOXDUO®IR development and registration
(26/07/2010)

Berthold Leibinger
Laserpreis 2010

(08/07/2010)

Uniseed’s Investment Manager Richard Marshall talks about Pepfactant’s win in the Enterprize Competition

QRxPharma Successfully Completes Pivotal Phase 3 Combination Rule Study for MoxDuo(R) IR in Patients with Post-Surgical Pain
(ASX Release, 14 April 2010)

Hatchtech Positive DeOvo Head Lice Phase II Clinical Trial Result(Media Release, 25 March 2010)

 
 
© 2007 Uniseed Pty Ltd